

In Te Application of:

Anderson, et al..

Art Unit: 1614

Serial No.: 09/763,216 Examiner: Not yet assigned

Filed: February 20, 2001 Atty. Docket: 0121-0005

For: Non-Peptide GnRH Agents, Methods and

Intermediates For Their Preparation

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Listed on the accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not

to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

⊠1.	This Information Disclosure Statement is being filed within three months of the U.S. filing date		
	OR before the mailing date of a first Office Action on the merits. No certification or fee is		
	required.		
□2.	The In	e Information Disclosure Statement is being filed more than three months after the U.S. filing	
	date AND after the mailing date of the first Office Action on the merits, but before the mailing date		
	of a Final Rejection or Notice of Allowance.		
	□а.	I hereby certify that each item of information contained in this Information Disclosure	
		Statement was cited in a communication from a foreign patent office in a counterpart	
		foreign application not more than three months prior to the filing of this Information	
		Disclosure Statement. 37 C.F.R. § 1.97(e)(1).	
	□b.	I hereby certify that no item of information in this Information Disclosure Statement was	
		cited in a communication from a foreign patent office in a counterpart foreign application	
		or, to my knowledge after making reasonable inquiry, was known to any individual	
		designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this	
		Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).	
	□с.	Attached is our check no in the amount of \$ in payment of the fee under	
		37 C.F.R. § 1.17(p).	
□3.	. This Information Disclosure Statement is being filed more than three months after the U		
	date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of		
	the Issue Fee. Applicants hereby petition that the Information Disclosure Statement be considered.		
	Attached is our check no in the amount of \$130.00 in payment of the fee under 37		
	C.F.R. § 1.17(i)(1).		
	□а.	I hereby certify that each item of information contained in this Information Disclosure	

Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).

□b. I hereby certify that no item of information on this Information Disclosure

Statement was cited in a communication from a foreign patent office in a counterpart

foreign application or, to my knowledge after making reasonable inquiry, was known to
any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the

filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

4. Relevance of the non-English language document(s) is discussed in the present specific	cation.
---	---------

Ì,

- ☐5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ⊠7. The Examiner's attention is directed to co-pending U.S. Patent Application Nos. 09/831,572, filed 5/11/01; Application 09/717,072, filed 11/22/00; Application No. 09/259,206, filed 3/1/99; and Application No. 60/295,812, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

☐8. Copies of the documents were cited by or submitted to the Office in Application No.
_______, filed _______, which is relied upon for an earlier filing date under 35 U.S.C.
§ 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0622

Respectfully submitted,

SHANKS & HERBERT

Reg. No. 37,628

Date: October 25, 2001

TransPotomac Plaza 1033 N. Fairfax Street Suite 306 Alexandria, VA 22314 703-683-3600